DelMar Pharmaceuticals, Inc. is a clinical and commercial stage drug development company with a focus on the treatment of cancer.
Quote | DelMar Pharmaceuticals (NASDAQ:DMPI)
Last: | $1.34 |
---|---|
Change Percent: | 7.2% |
Open: | $1.22 |
Close: | $1.34 |
High: | $1.35 |
Low: | $1.17 |
Volume: | 1,321,048 |
Last Trade Date Time: | 08/19/2020 04:58:56 pm |
News | DelMar Pharmaceuticals (NASDAQ:DMPI)
DelMar Pharmaceuticals ( DMPI +6.9% ) announces direct offering of 19,587 convertible preferred shares for the gross proceeds of ~$19.6M. That makes the offering priced at-the-market on $1,000 per share. More news on: DelMar Pharmaceuticals, Inc., , Stocks on the move, Healthcar...
SAN DIEGO , Aug. 18, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company") announced today that it has entered into definitive agreements with investors providing for the sale and issuance of up to 19,587 shares of its Series C Convert...
Message Board Posts | DelMar Pharmaceuticals (NASDAQ:DMPI)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
DelMar Pharmaceuticals Company Name:
DMPI Stock Symbol:
NASDAQ Market:
SAN DIEGO , Aug. 18, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company") announced today that it has entered into definitive agreements with investors providing for the sale and issuance of up to 19,587 shares of its Series C Convert...
SAN DIEGO , Aug. 17, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company") announced today that all proposals related to the proposed merger between DelMar and Adgero were approved by DelMar's stockholders at a special meeting held on August 14...
SAN DIEGO , July 17, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies announced today that it will be conducting a conference call to discuss...